Pricing Log in Create free account

Alzamend Neuro, Inc. (ALZN) vs Can-Fite Biopharma Ltd (CANF)

Alzamend Neuro, Inc. and Can-Fite Biopharma Ltd are both Biotechnology companies. Alzamend Neuro, Inc. and Can-Fite Biopharma Ltd are of similar size ($6.2M and $5.6M). Alzamend Neuro, Inc. has the higher net margin (0.00% vs −1,148.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Alzamend Neuro, Inc. leads on 6 and Can-Fite Biopharma Ltd on 4.

Valuation

Metric ALZN CANF Biotechnology median
P/E n/m n/m 8.50
P/S n/m 0.45 9.71
P/B 1.02 0.07 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.15 0.58 0.64
EV/Sales n/m (8.64) 9.21
Earnings yield (174.24%) (738.94%) (33.15%)
Free cash flow yield (120.83%) (5,538.69%) (25.50%)

Profitability

Metric ALZN CANF Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (1,148.62%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.23%) 0.00% (56.36%)
Return on assets (122.36%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN CANF Biotechnology median
Revenue growth (TTM) — (3.36%) 6.02%
EPS growth (last fiscal year) 76.77% 45.23% 30.26%
Revenue growth, 5-year CAGR — (11.90%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN CANF Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 3.60 4.72
Net debt to EBITDA 0.08 0.86 0.96

Dividend

Metric ALZN CANF Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALZN CANF Biotechnology median
Market cap 6.17m 5.61m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack